BioLineRx Ltd. (TLV:BLRX)
Israel
· Delayed Price · Currency is ILS · Price in ILA 1.900
+0.100 (5.26%)
May 5, 2025, 11:35 AM IDT
BioLineRx Revenue
In the year 2024, BioLineRx had annual revenue of $28.94M USD with 502.92% growth. BioLineRx had revenue of $11.75M in the quarter ending December 31, 2024, with 144.77% growth.
Revenue
$28.94M
Revenue Growth
+502.92%
P/S Ratio
0.40
Revenue / Employee
$1.03M
Employees
28
Market Cap
42.42M ILS
Revenue Chart
* This company reports financials in USD.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Teva Pharmaceutical Industries | 60.26B |
| Danel (Adir Yeoshua) | 2.77B |
| Kamada | 586.24M |
| Bait Bakfar | 103.40M |
| Novolog (Pharm-Up 1966) | 2.02B |
| Ilex Medical | 920.37M |
| BrainsWay | 149.39M |
| SofWave Medical | 217.27M |
BioLineRx News
- 4 weeks ago - BioLineRx Ltd. (BLRX) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - BioLineRx GAAP EPS of -$0.01, revenue of $28.94M - Seeking Alpha
- 4 weeks ago - BioLineRx Reports 2024 Financial Results and Provides Corporate Update - PRNewsWire
- 5 weeks ago - BioLineRx Q4 2024 Earnings Preview - Seeking Alpha
- 5 weeks ago - Uncovering Potential: BioLine Rx's Earnings Preview - Benzinga
- 5 weeks ago - BioLineRx to Report 2024 Annual Results on March 31, 2025 - PRNewsWire
- 3 months ago - BioLineRx Issues Letter to Shareholders - PRNewsWire
- 3 months ago - BioLineRx announces change to ratio of ADS to ordinary shares - Seeking Alpha